Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: Modelling the clinical and economic implications

PharmacoEconomics

Volumn 27, Issue 1, 2009, Pages 39-53

  Guo, Shien ^a,b   Bozkaya, Duygu ^a   Ward, Alexandra ^a   O'Brien, Judith A ^a   Ishak, Khajak ^c   Bennett, Randy ^d   Al Sabbagh, Ahmad ^d   Meletiche, Dennis M ^d  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

^c UNITED BIOSOURCE CORPORATION   (Canada)

^d EMD SERONO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISABILITY; DRUG EFFICACY; DRUG MEGADOSE; ECONOMIC ASPECT; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT;

COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MODELS, ECONOMIC; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 59049099995     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200927010-00005     Document Type: Article

References (39)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000; 343: 938-52
2. Mayr WT, Pittock SJ, McClelland RL, et al. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota 1985-2000. Neurology 2003; 61: 1373-7
3. Kantarci O, Wingerchuk D. Epidemiology and natural history of multiple sclerosis: new insights. Curr Opin Neurol 2006; 19: 248-54
4. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I: clinical course and disability. Brain 1989; 112:133-46
5. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2: predictive value of the early clinical course. Brain 1989; 112: 1419-28
6. Kantarci O, Siva A, Eraksoy M, et al. Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 1998; 51: 765-72
7. Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006; 66: 1696-702
8. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504
9. PRISMS Study Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 26: 56 (12): 1628-36
10. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-94
11. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002; 59 (10): 1480-1
12. Panitch H, Goodin D, Francis G, et al. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci 2005; 15: 239 (1): 67-74
13. Tappenden P, Chilcott J, O'Hagan T, et al. Cost-effectiveness of beta interferons and glatiramer acetate in the management of multiple sclerosis: final report to the National Institute for Clinical Excellence [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/msscharrreport.pdf [Accessed 2006 Sep 9]
14. Prosser LA, Kuntz KM, Bar-Or A, et al. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health 2004; 7: 554-68
15. Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm 2007; 13: 245-61
16. Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 2005; 23(4): 323-32
17. Caro JJ, Guo S, Ward A, et al. Modelling the economic and health consequences of cardiac resynchronization therapy in the UK. Curr Med Res Opin 2006 Jun; 22 (6): 1171-9
18. McEwan P, Baboolal K, Conway P, et al. Evaluation of the cost-effectiveness of sirolimus versus cyclosporin for immunosuppression after renal transplantation in the United Kingdom. Clin Ther 2005; 27: 1834-46
19. Guest JF, Cookson RF. Cost of schizophrenia to UK Society: an incidence-based cost-of-illness model for the first 5 years following diagnosis. Pharmacoeconomics 1999; 15(6): 597-610
20. Cooper K, Davies R, Roderick P, et al. The development of a simulation model of the treatment of coronary heart disease. Health Care Manag Sci 2002; 5: 259-67
21. McEwan P, Peters JR, Bergenheim K, et al. Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Curr Med Res Opin 2006; 22: 121-9
22. Bozzette SA, Boer R, Bhatnagar V, et al. A model for a smallpox-vaccination policy. N Engl J Med 2003; 348: 416-25
23. Freedman MS, Patry DG, Grand'Maison F, et al. Treatment optimization in multiple sclerosis. Can J Neurol Sci 2004; 31: 157-68
24. Schwid SR, Thorpe J, Sharief M, et al. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. Arch Neurol 2005; 62 (5): 785-92
25. Sandberg-Wollheim M, Bever C, Carter J, et al. Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. J Neurol 2005; 252 (1):8-13
26. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
27. Held U, Heigenhauser L, Shang C, et al. Predictors of relapse rate in MS clinical trials. Neurology 2005; 65: 1769-73
28. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-85
29. Richert ND, Zierak MC, Bash CN, et al. MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b. Mult Scler 2000; 6: 86-90
30. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993; 116: 117-34
31. Center for Disease Control. US life table 2003 [online]. Available from URL: http://www.cdc.gov/nchs/data/nvsr/nvsr54/nvsr54-14.pdf [Accessed 2006 Nov 10]
32. Poser S, Kurtzke JF, Poser W, et al. Survival in multiple sclerosis. J Clin Epidemiol 1989; 42: 159-68
33. Drug topics red book. Montvale (NJ): Medical Economics, 2007
34. O'Brien JA, Ward AJ, Patrick AR, et al. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003; 3 (1): 17-29
35. Grima DT, Torrance GW, Francis G, et al. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler 2000; 6: 91-8
36. Kelton WD, Sadowski RP, Sadowski DA. Simulation with ARENA. 3rd ed. Boston (MA): McGraw-Hill, 2003
37. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-11
38. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003; 61:1528-32
39. Zivadinov R, Zorzon M, Tommasi MA, et al. A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. J Neurol Sci 2003; 216: 113-8